0. Advocacy Graphic

 Leading the movement to transform America's addiction treatment infrastructure and expand access to research-validated, results-based care


ASAM's Advocacy Principles

Advocacy Webpage Graphics Teach It
TEACH addiction medicine by expanding and strengthening our workforce and dispelling stigma
Advocacy Webpage Graphics Standardize It
STANDARDIZE the delivery of addiction medicine so that more patients receive high-quality, evidence-based care
0. Advocacy Webpage Graphics Cover It
COVER addiction medicine in a way that expands patient access to coordinated, comprehensive care
Advocacy Homepage HR 6 Graphic

It's time we treat addiction like other chronic diseases 


Advocacy Committees & Councils

ASAM's advocacy could not happen if not for the dedicated effort of our members.

0. Find a Policy Statement 1 - cropped

Public Policy Statements

Learn about ASAM's position on current policy issues.

Teamwork - smallest


ASAM is proud to work collaboratively with others to improve the lives of those living with addiction.
0. Advocacy Toolkits

Advocacy Toolkits

ASAM provides toolkits to help you advocate for public policies that advance addiction medicine and promote access to treatment

Legislative Tracker Graphic


ASAM Endorses ACMT’s Position Statement on Buprenorphine Administration in the Emergency Department

by | Sep 09, 2019


On July 17, ASAM’s Board of Directors approved ASAM’s endorsement of the American College of Medical Toxicology's position statement "Buprenorphine Administration in the Emergency Department." The policy statement acknowledges the increasing number of opioid-related emergency department (ED) visits and fatalities occurring across the nation, before endorsing the administration of buprenorphine to appropriate patients in the ED to treat opioid withdrawal and to reduce the risk of opioid overdose and death following discharge, as well as the administration of buprenorphine in the ED as a bridge to long-term addiction treatment.


The statement stresses the importance of empowering EDs with the ability to administer buprenorphine, noting that EDs see a large number of patients presenting with opioid overdose, opioid withdrawal, or opioid use disorder (OUD). Furthermore, the ED can be many people’s primary access point to health care and treatment, and evaluation in the ED represents an opportunity to engage patients in a discussion of opioid agonist therapy and harm reduction strategies to mitigate risk from the continued use of illicit drugs after discharge. As the opioid overdose epidemic continues to take lives across the country, it is vital that the addiction treatment workforce receive training and resources to provide treatment in many different settings for those suffering with OUD.


Read the full policy statement here.